GlobeNewswire
Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency interaction results in recommendation to commence Phase I/II Clinical Trial in NASH Patients LONDON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (“Genflow” or “the Company”) (LSE:GENF) (OTCQB:GENFF), today announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgiu